SRR1346813
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.447
- TNFA_SIGNALING_VIA_NFKB+0.366
- IL2_STAT5_SIGNALING+0.338
- INFLAMMATORY_RESPONSE+0.334
- ANDROGEN_RESPONSE+0.323
- ALLOGRAFT_REJECTION+0.321
- IL6_JAK_STAT3_SIGNALING+0.306
- BILE_ACID_METABOLISM+0.292
- INTERFERON_ALPHA_RESPONSE+0.278
- COMPLEMENT+0.276
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.435
- MYC_TARGETS_V2-0.413
- E2F_TARGETS-0.340
- G2M_CHECKPOINT-0.329
- OXIDATIVE_PHOSPHORYLATION-0.285
- SPERMATOGENESIS-0.267
- DNA_REPAIR-0.247
- PANCREAS_BETA_CELLS-0.214
- WNT_BETA_CATENIN_SIGNALING-0.207
- MYC_TARGETS_V1-0.182
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1340133 | GTEX | — | 0.923 |
| 2 | SRR1350525 | GTEX | — | 0.908 |
| 3 | SRR612407 | GTEX | — | 0.908 |
| 4 | BS_47SJZ3PH | low-grade glioma | — | 0.904 |
| 5 | SRR1488538 | GTEX | — | 0.902 |
| 6 | SRR1486304 | GTEX | — | 0.898 |
| 7 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.895 |
| 8 | SRR1368856 | GTEX | — | 0.891 |
| 9 | SRR1446828 | GTEX | — | 0.889 |
| 10 | SRR615731 | GTEX | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.447 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.366 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.338 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.334 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.323 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.321 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.306 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.292 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.278 | Inavolisib | — uncovered |
| COMPLEMENT | 0.276 | Inavolisib | — uncovered |
| APOPTOSIS | 0.274 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.268 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.244 | Inavolisib | — uncovered |
| HYPOXIA | 0.241 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.222 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.201 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.183 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.182 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.177 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.177 | Inavolisib | — uncovered |